Pan Tong
Papers
1
Total Citations
49
H-Index
1
About
Pan Tong is a leading investigator in cancer biology, with a focused expertise in cell cycle regulation and targeted therapeutics for lung cancer. His work centers on the mechanisms of anaphase catastrophe—a form of mitotic cell death triggered by multipolar anaphase in cells with supernumerary centrosomes. Tong’s major contribution lies in advancing next-generation CDK inhibitors, specifically CDK2/9 inhibitors, as potent anticancer agents. His seminal 2016 study on CCT68127 demonstrated how this novel compound selectively induces anaphase catastrophe and apoptosis in lung cancer cells, building upon earlier work with first-generation inhibitors like seliciclib. With 49 citations, this paper has become a cornerstone for understanding how CDK2/9 blockade exploits centrosome amplification—a common vulnerability in aggressive tumors. Tong’s research bridges fundamental cell cycle biology with translational drug development, offering a rational strategy to overcome resistance in lung cancer. His achievements include elucidating the molecular triggers of anaphase catastrophe and validating CDK2/9 as druggable targets, positioning him as a key figure in the quest for more effective, less toxic cancer therapies.
Research Focus
Key Achievements
Top Papers
- 1Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer49 citations · 2016